Clinical experience of leukapheresis for CD19 CAR-T cell therapy

DOI Web Site PubMed 1 Citations
  • JO Tomoyasu
    Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital Department of Hematology and Oncology, Kyoto University Hospital
  • YOSHIHARA Satoru
    Department of Transfusion Medicine and Cell Therapy, Hyogo College of Medicine Hospital Department of Hematology, Hyogo College of Medicine Hospital
  • ARAI Yasuyuki
    Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital Department of Hematology and Oncology, Kyoto University Hospital
  • IKEMOTO Junko
    Department of Transfusion Medicine and Cell Therapy, Hyogo College of Medicine Hospital
  • ONOMOTO Hitomi
    Department of Transfusion Medicine and Cell Therapy, Hyogo College of Medicine Hospital
  • SUGIYAMA Hiroki
    Department of Transfusion Medicine and Cell Therapy, Hyogo College of Medicine Hospital
  • YOSHIHARA Kyoko
    Department of Transfusion Medicine and Cell Therapy, Hyogo College of Medicine Hospital Department of Hematology, Hyogo College of Medicine Hospital
  • MATSUI Keiko
    Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital
  • NIWA Norimi
    Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital
  • NAKAGAWA Yoko
    Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital
  • KITAWAKI Toshio
    Department of Hematology and Oncology, Kyoto University Hospital
  • KANDA Junya
    Department of Hematology and Oncology, Kyoto University Hospital
  • TAKAORI-KONDO Akifumi
    Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital Department of Hematology and Oncology, Kyoto University Hospital
  • NAGAO Miki
    Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital

Bibliographic Information

Other Title
  • CD19 CAR-T細胞療法における白血球アフェレーシスの経験
  • CD19 CAR-T細胞療法における白血球アフェレーシスの経験 : 国内最多2施設による共同研究
  • CD19 CAR-Tサイボウ リョウホウ ニ オケル ハッケッキュウ アフェレーシス ノ ケイケン : コクナイ サイタ 2 シセツ ニ ヨル キョウドウ ケンキュウ
  • —国内最多2施設による共同研究—

Search this article

Description

<p>To perform chimeric antigen receptor T (CAR-T) cell therapy in heavily pretreated patients with progressive disease and depleted lymphocytes, an optimized leukapheresis protocol must be established. To probe the effects of patient-related parameters on the collection efficiency of CD3+ cells, we retrospectively analyzed patients with relapsed/refractory diffuse large B-cell lymphoma who underwent leukapheresis for tisagenlecleucel at two centers. A total of 51 patients were analyzed, with a median age at apheresis of 59 years, and precollection hemoglobin levels, CD3+ cell counts, and platelet counts of 9.2 g/dl, 574/µl, and 15.8×104/µl, respectively. A median of 3.0×109 (0.7-8.4) CD3+ cells were harvested with 8.7 (4.0-15.7) l apheresis volume. The collection efficiency 2 (CE2) for CD3+ cells was 61.0% (21.0-127.3). One-day apheresis was sufficient to obtain the designated cell numbers in all cases. Lower hemoglobin levels, higher CD3+ cell counts, and higher platelet counts before apheresis were significantly associated with lower CE2 for CD3+ cells. These results suggest a need to increase the apheresis volume in anemic, lymphocyte- or platelet-rich patients due to an expected low CE2. Erythrocyte transfusions before or during apheresis may be a reasonable option for patients with anemia.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 62 (3), 163-169, 2021

    The Japanese Society of Hematology

Citations (1)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top